CA2085127C - Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease - Google Patents

Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease Download PDF

Info

Publication number: CA2085127C
Authority: CA; Canada
Prior art keywords: amyloid; protein; sequence; promoter; sequences
Prior art date: 1990-06-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002085127A

Other languages

English (en)

French (fr)

Other versions

CA2085127A1 (en

Inventor

Barbara Cordell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scios LLC

Original Assignee

Scios Nova Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-15

Filing date

1991-06-17

Publication date

2002-12-10

1991-06-17 Application filed by Scios Nova Inc filed Critical Scios Nova Inc

1991-12-16 Publication of CA2085127A1 publication Critical patent/CA2085127A1/en

2002-12-10 Application granted granted Critical

2002-12-10 Publication of CA2085127C publication Critical patent/CA2085127C/en

2011-06-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000009261 transgenic effect Effects 0.000 title abstract description 64
208000024827 Alzheimer disease Diseases 0.000 title abstract description 31
230000007170 pathology Effects 0.000 title abstract description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 219
102000004169 proteins and genes Human genes 0.000 claims abstract description 181
239000002243 precursor Substances 0.000 claims abstract description 55
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 44
238000011830 transgenic mouse model Methods 0.000 claims abstract description 29
241000699670 Mus sp. Species 0.000 claims abstract description 20
235000013601 eggs Nutrition 0.000 claims abstract description 16
210000000944 nerve tissue Anatomy 0.000 claims abstract description 12
230000014509 gene expression Effects 0.000 claims description 61
210000004556 brain Anatomy 0.000 claims description 52
238000000034 method Methods 0.000 claims description 51
150000001413 amino acids Chemical class 0.000 claims description 28
238000004519 manufacturing process Methods 0.000 claims description 28
208000037259 Amyloid Plaque Diseases 0.000 claims description 22
241000699666 Mus <mouse, genus> Species 0.000 claims description 22
230000001537 neural effect Effects 0.000 claims description 16
230000008569 process Effects 0.000 claims description 10
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 9
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 8
102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 6
108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 6
108091005508 Acid proteases Proteins 0.000 claims description 4
102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 4
108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 4
241000124008 Mammalia Species 0.000 abstract description 23
241000699660 Mus musculus Species 0.000 abstract description 22
210000001519 tissue Anatomy 0.000 abstract description 17
150000001875 compounds Chemical class 0.000 abstract description 5
238000001727 in vivo Methods 0.000 abstract description 4
229940122055 Serine protease inhibitor Drugs 0.000 abstract description 2
239000003001 serine protease inhibitor Substances 0.000 abstract description 2
101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 109
239000012634 fragment Substances 0.000 description 62
239000013612 plasmid Substances 0.000 description 62
210000004027 cell Anatomy 0.000 description 51
108020004414 DNA Proteins 0.000 description 44
239000013598 vector Substances 0.000 description 39
241001465754 Metazoa Species 0.000 description 37
101710132601 Capsid protein Proteins 0.000 description 34
229940024606 amino acid Drugs 0.000 description 29
235000001014 amino acid Nutrition 0.000 description 28
108090000765 processed proteins & peptides Proteins 0.000 description 24
239000003814 drug Substances 0.000 description 22
238000010276 construction Methods 0.000 description 21
229940079593 drug Drugs 0.000 description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
230000004927 fusion Effects 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
201000010099 disease Diseases 0.000 description 16
210000004940 nucleus Anatomy 0.000 description 16
102000003792 Metallothionein Human genes 0.000 description 15
108090000157 Metallothionein Proteins 0.000 description 15
230000002068 genetic effect Effects 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 13
238000010367 cloning Methods 0.000 description 13
230000029087 digestion Effects 0.000 description 13
230000009466 transformation Effects 0.000 description 13
125000003275 alpha amino acid group Chemical group 0.000 description 12
239000013613 expression plasmid Substances 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
239000000523 sample Substances 0.000 description 12
238000010186 staining Methods 0.000 description 12
108700039691 Genetic Promoter Regions Proteins 0.000 description 11
239000002299 complementary DNA Substances 0.000 description 11
239000013604 expression vector Substances 0.000 description 10
210000004962 mammalian cell Anatomy 0.000 description 10
238000012360 testing method Methods 0.000 description 10
108020004705 Codon Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
108700019146 Transgenes Proteins 0.000 description 9
239000000463 material Substances 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
210000002569 neuron Anatomy 0.000 description 9
210000004681 ovum Anatomy 0.000 description 9
239000013615 primer Substances 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
239000000047 product Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
101710094503 Metallothionein-1 Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
210000000349 chromosome Anatomy 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
238000001262 western blot Methods 0.000 description 8
UAHFGYDRQSXQEB-PWPYQVNISA-N 4-nle-α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-PWPYQVNISA-N 0.000 description 7
102000009091 Amyloidogenic Proteins Human genes 0.000 description 7
108010048112 Amyloidogenic Proteins Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
241000700159 Rattus Species 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
108091026898 Leader sequence (mRNA) Proteins 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
108020005187 Oligonucleotide Probes Proteins 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
238000002105 Southern blotting Methods 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
210000002257 embryonic structure Anatomy 0.000 description 6
-1 i.e. Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
239000002751 oligonucleotide probe Substances 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
230000010076 replication Effects 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
102000004594 DNA Polymerase I Human genes 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 5
102000002322 Egg Proteins Human genes 0.000 description 5
108010000912 Egg Proteins Proteins 0.000 description 5
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
241000700618 Vaccinia virus Species 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000008021 deposition Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
230000002792 vascular Effects 0.000 description 5
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000012192 Cystatin C Human genes 0.000 description 4
108010061642 Cystatin C Proteins 0.000 description 4
239000003155 DNA primer Substances 0.000 description 4
201000010374 Down Syndrome Diseases 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
206010044688 Trisomy 21 Diseases 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
210000001320 hippocampus Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000002682 neurofibrillary tangle Anatomy 0.000 description 4
CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical group C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000000844 transformation Methods 0.000 description 4
230000014616 translation Effects 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
102000007469 Actins Human genes 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108091029865 Exogenous DNA Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
108010086093 Mung Bean Nuclease Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091036066 Three prime untranslated region Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
210000001840 diploid cell Anatomy 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
230000006870 function Effects 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000016361 genetic disease Diseases 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000000971 hippocampal effect Effects 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
108091006086 inhibitor proteins Proteins 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000010354 integration Effects 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000008186 parthenogenesis Effects 0.000 description 3
230000007505 plaque formation Effects 0.000 description 3
210000002763 pyramidal cell Anatomy 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012250 transgenic expression Methods 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
208000023769 AA amyloidosis Diseases 0.000 description 2
208000023761 AL amyloidosis Diseases 0.000 description 2
230000007082 Aβ accumulation Effects 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010007509 Cardiac amyloidosis Diseases 0.000 description 2
206010008111 Cerebral haemorrhage Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
241000701460 JC polyomavirus Species 0.000 description 2
208000009018 Medullary thyroid cancer Diseases 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
108010071690 Prealbumin Proteins 0.000 description 2
102000007584 Prealbumin Human genes 0.000 description 2
206010036673 Primary amyloidosis Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
206010039811 Secondary amyloidosis Diseases 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
102000054727 Serum Amyloid A Human genes 0.000 description 2
108700028909 Serum Amyloid A Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
208000033781 Thyroid carcinoma Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000010586 diagram Methods 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
230000002518 glial effect Effects 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
239000003999 initiator Substances 0.000 description 2
230000003585 interneuronal effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000009456 molecular mechanism Effects 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000005015 neuronal process Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000001936 parietal effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000001322 periplasm Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
210000001103 thalamus Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
208000013077 thyroid gland carcinoma Diseases 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
201000007905 transthyretin amyloidosis Diseases 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
208000018282 ACys amyloidosis Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
208000021563 Alzheimer disease 1 Diseases 0.000 description 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
241000713842 Avian sarcoma virus Species 0.000 description 1
241000283725 Bos Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241001288713 Escherichia coli MC1061 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
101000958041 Homo sapiens Musculin Proteins 0.000 description 1
101000964562 Homo sapiens Zinc finger FYVE domain-containing protein 9 Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
241001045988 Neogene Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
101710115194 Protease inhibitor 1 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010078762 Protein Precursors Proteins 0.000 description 1
102000014961 Protein Precursors Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
102100040801 Zinc finger FYVE domain-containing protein 9 Human genes 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000003322 aneuploid effect Effects 0.000 description 1
208000036878 aneuploidy Diseases 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
101150042295 arfA gene Proteins 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
210000001109 blastomere Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015111 chews Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
108091092330 cytoplasmic RNA Proteins 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000003255 drug test Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
210000001879 hippocampal ca1 region Anatomy 0.000 description 1
102000046949 human MSC Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
108010077055 methylated bovine serum albumin Proteins 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000004784 molecular pathogenesis Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
238000010449 nuclear transplantation Methods 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
101150087557 omcB gene Proteins 0.000 description 1
101150115693 ompA gene Proteins 0.000 description 1
210000002380 oogonia Anatomy 0.000 description 1
230000008212 organismal development Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
101150009573 phoA gene Proteins 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
210000004508 polar body Anatomy 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940070353 protamines Drugs 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
210000004336 spermatogonium Anatomy 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
230000010415 tropism Effects 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Environmental Sciences (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002085127A 1990-06-15 1991-06-17 Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease Expired - Lifetime CA2085127C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53885790A	1990-06-15	1990-06-15
US538,857		1990-06-15
PCT/US1991/004447 WO1991019810A1 (en)	1990-06-15	1991-06-17	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease

Publications (2)

Publication Number	Publication Date
CA2085127A1 CA2085127A1 (en)	1991-12-16
CA2085127C true CA2085127C (en)	2002-12-10

Family

ID=24148714

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002085127A Expired - Lifetime CA2085127C (en)	1990-06-15	1991-06-17	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease

Country Status (9)

Country	Link
US (1)	US5387742A (de)
EP (1)	EP0647268B1 (de)
JP (1)	JPH06507782A (de)
AT (1)	ATE260974T1 (de)
AU (1)	AU646877B2 (de)
CA (1)	CA2085127C (de)
DE (1)	DE69133372T2 (de)
ES (1)	ES2217250T3 (de)
WO (1)	WO1991019810A1 (de)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5912410A (en) *	1990-06-15	1999-06-15	Scios Inc.	Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
ES2236682T5 (es)	1991-01-21	2011-03-31	Elan Pharmaceuticals, Inc.	Ensayo y modelo para la enfermedad de alzheimer.
US5672805A (en) *	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
AU2765992A (en)	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
WO1993007280A1 (en) *	1991-10-04	1993-04-15	The Government Of The United States Of America As Represented By The Department Of Health And Human Services	Astrocyte-specific transcription of human genes
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
AU671093B2 (en) *	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) *	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) *	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) *	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US6264915B1 (en)	1992-09-13	2001-07-24	The President And Fellows Of Harvard College	Process for detecting potential carcinogens
DE69334337D1 (de) *	1992-10-26	2010-08-26	Elan Pharm Inc	Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
US5605811A (en) *	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
CA2125467C (en) *	1993-07-06	2001-02-06	Heinz Dobeli	Process for producing hydrophobic polypeptides, proteins or peptides
GB9316727D0 (en) *	1993-08-12	1993-09-29	Inst Of Psychiatry	Models of alzheimers's disease
GB2295395B (en) *	1993-08-12	1998-04-01	Inst Of Psychiatry	Models of Alzheimer's disease
AU702293B2 (en) *	1993-10-27	1999-02-18	Athena Neurosciences, Inc.	Transgenic animals harboring APP allele having Swedish mutation
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE69533583T2 (de)	1994-01-27	2005-10-06	Regents of the University of Minnesota, Southeast, Minneapolis	Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US6025183A (en) *	1994-02-28	2000-02-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Transgenic animal assay system for anti-cholinesterase substances
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
US6020537A (en) *	1994-05-13	2000-02-01	The Regents Of The University Of California	Prion protein standard and method of making same
US5792901A (en) *	1994-05-13	1998-08-11	The Regents Of The University Of California	Detecting prions in a sample and prion preparation and transgenic animal used for same
US6008435A (en) *	1994-05-13	1999-12-28	The Regents Of The University Of California	Detecting cow, sheep and human prions in a sample and transgenic mice used for same
WO1995034640A1 (en) *	1994-06-13	1995-12-21	Henry Ford Health System	A novel neuronal-neonatal gene: neuronatin
US5686269A (en) *	1994-07-28	1997-11-11	The Mclean Hospital Corporation	Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
WO1996006927A1 (en) *	1994-09-01	1996-03-07	Merck & Co., Inc.	Transgenic animal expressing a familial form of human amyloid precursor protein
US7427392B1 (en)	1994-11-14	2008-09-23	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030152909A1 (en) *	1994-11-16	2003-08-14	Mitrani Eduardo N.	In vitro micro-organs, and uses related thereto
US5698766A (en) *	1995-04-05	1997-12-16	The Regents Of The University Of California	Transgenic animal model for testing drugs for treating eating disorders and epilepsy
US5817911A (en) *	1995-04-07	1998-10-06	Regents Of The University Of California	Transgenic mice expressing alveolar MCP-1
US5777194A (en) *	1995-04-26	1998-07-07	Cephalon, Inc.	Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US5986054A (en) *	1995-04-28	1999-11-16	The Hospital For Sick Children, Hsc Research And Development Limited Partnership	Genetic sequences and proteins related to alzheimer's disease
DE69629563T2 (de)	1995-05-03	2004-07-22	The President And Fellows Of Harvard College, Cambridge	Bestimmung der funktion von calcineurin in immunosuppression und neurotoxizität
US5777093A (en) *	1995-05-16	1998-07-07	Ramot-University Authority For Applied Research & Industrial Development Ltd.	cDNAs associated with ataxia-telangiectasia
US5728807A (en) *	1995-05-16	1998-03-17	Ramot-University Authority For Applied Research And Industrial Development, Ltd.	Mutated proteins associated with ataxia-telangiectasia
US5858661A (en)	1995-05-16	1999-01-12	Ramot-University Authority For Applied Research And Industrial Development	Ataxia-telangiectasia gene and its genomic organization
US6187991B1 (en)	1995-05-23	2001-02-13	Pfizer Inc	Transgenic animal models for type II diabetes mellitus
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
AU6343196A (en) *	1995-07-18	1997-02-18	University Of South Florida	Mutant s182 genes
US6248555B1 (en)	1995-08-31	2001-06-19	The General Hospital Corporation	Genetic alterations related to familial alzheimer's disease
KR19990044317A (ko) *	1995-09-01	1999-06-25	라미 핀클러 ; 하나넬 크바탄스키	아밀포스파타제2Ｃ - ＰＰ 2Ｃα-발현의 조작 및 검출
US5859311A (en) *	1995-11-27	1999-01-12	University Of Kentucky Research Foundation	Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
WO1997025412A1 (en)	1996-01-09	1997-07-17	The Regents Of The University Of California	Ungulate embryonic stem-like cells, methods of making and using the cells to produce transgenic ungulates
WO1997025413A1 (en)	1996-01-09	1997-07-17	The Regents Of The University Of California	Ungulate embryonic stem-like cells, making and using the cells to produce a transgenic ungulate
JP2000506375A (ja) *	1996-01-26	2000-05-30	エイチエスシーリサーチアンドデベロップメントリミテッドパートナーシップ	アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
US6140309A (en) *	1996-03-12	2000-10-31	University Of South Florida	Vasoactive effects and free radical generation by β-amyloid peptides
US6077697A (en) *	1996-04-10	2000-06-20	Chromos Molecular Systems, Inc.	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) *	1996-04-10	2003-02-13	Gyula Hadlaczky	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) *	1996-04-10	2002-10-31	Gyula Hadlaczky	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
CA2259123C (en)	1996-07-01	2003-10-21	Lorus Therapeutics Inc.	Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
AU4503497A (en)	1996-09-26	1998-04-17	Leinwand, Leslie A.	Transgenic model for heart failure
US5849999A (en) *	1996-10-16	1998-12-15	The Mclean Hospital Corporation	Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
EP0973923A1 (de) *	1997-02-24	2000-01-26	Hoechst Marion Roussel, Inc.	Verbesserte tests für die beta-amyloid prozessierung
US5962669A (en) *	1997-06-02	1999-10-05	The Regents Of The University Of California	Nucleic acid encoding prion protein variant
CA2287848A1 (en)	1997-06-02	1998-12-10	The Regents Of The University Of California	Prion protein modulator factor (ppmf) and prion resistant animals
US7973156B2 (en) *	1997-08-21	2011-07-05	Quark Pharmaceuticals Inc.	Hypoxia-regulated genes
US20030104973A1 (en) *	1997-08-21	2003-06-05	Quark Biotech, Inc.	Hypoxia-regulated genes
DE69829857T2 (de)	1997-08-21	2006-02-02	Quark Biotech, Inc., Pleasanton	Hypoxie-regulierte gene
US6455757B1 (en)	1997-10-08	2002-09-24	The Regents Of The University Of California	Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
US6175057B1 (en)	1997-10-08	2001-01-16	The Regents Of The University Of California	Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) *	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6761888B1 (en) *	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) *	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7687057B2 (en)	1998-01-09	2010-03-30	Yissum Research Development Company Of The Hebrew University Of Jerusalem	In vitro micro-organs, and uses related thereto
EP2009109A1 (de)	1998-01-12	2008-12-31	Pedro Jose	G-Protein-bezogene Kinase-Mutanten in starkem Bluthochdruck
US20050059802A1 (en) *	1998-04-07	2005-03-17	Neuralab Ltd	Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) *	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
ATE481487T1 (de)	1998-11-27	2010-10-15	Ucb Sa	Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
EP1140973A4 (de) *	1998-12-22	2002-10-30	Myriad Genetics Inc	Protein-protein wechselwirkungen in neurodegenerativen erkrankungen
EP1026251A3 (de) *	1999-02-03	2000-09-06	Pfizer Products Inc.	Transgene Tiere welche das menschliche p25 Gen exprimieren
US6911429B2 (en) *	1999-04-01	2005-06-28	Transition Therapeutics Inc.	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en)	1999-04-01	2005-03-08	Eva A. Turley	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20030131364A1 (en) *	1999-04-27	2003-07-10	Karen Duff	Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
US6670195B1 (en)	1999-05-26	2003-12-30	New York University	Mutant genes in Familial British Dementia and Familial Danish Dementia
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en) *	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20070160615A1 (en) *	1999-06-01	2007-07-12	Jun Tan	Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
US6787318B1 (en) *	1999-06-01	2004-09-07	Roskamp Research Institute, Llc	Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
JP2003535025A (ja) *	1999-06-25	2003-11-25	イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム	微小器官で血管新生を誘発する方法
US20060127366A1 (en) *	1999-06-25	2006-06-15	Mitrani Eduardo N	Method and device for inducing biological processes by micro-organs
US6875582B1 (en)	1999-08-19	2005-04-05	Omniscience Pharmaceuticals, Inc.	Methods and targets of antibiotic resistance
US6998232B1 (en)	1999-09-27	2006-02-14	Quark Biotech, Inc.	Methods of diagnosing bladder cancer
WO2001044269A2 (en) *	1999-12-17	2001-06-21	Large Scale Proteomics Corporation	Brain protein markers
AU2001225441A1 (en) *	2000-01-24	2001-07-31	Agricultural Research Organization The Volcani Center	Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
DE60124080T2 (de)	2000-03-23	2007-03-01	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
JP2003530437A (ja) *	2000-04-13	2003-10-14	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	Ａβ４２低下物質
US6713276B2 (en) *	2000-06-28	2004-03-30	Scios, Inc.	Modulation of Aβ levels by β-secretase BACE2
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
JP2004502664A (ja) *	2000-06-30	2004-01-29	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病処置用化合物
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
HUP0300810A2 (hu)	2000-07-20	2003-08-28	M.G.V.S. Ltd.	Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
US7919670B1 (en)	2000-08-14	2011-04-05	The Trustees Of Columbia University In The City Of New York	Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
CN101845446B (zh) *	2000-09-28	2016-01-20	生物源食物及科学公司	脂肪酸去饱和酶家族成员fad4、fad5、fad5-2和fad6及它们的应用
PE20020574A1 (es) *	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
US20030051266A1 (en) *	2001-02-14	2003-03-13	Serafini Tito Andrew	Collections of transgenic animal lines (living library)
US7081561B2 (en) *	2001-03-16	2006-07-25	The Regents Of The University Of California	Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
EP1377156A4 (de) *	2001-03-22	2007-08-29	Scentgene Pollination Ltd	Verfahren zur förderung von entomophilen
EP1967525B1 (de)	2001-05-08	2012-11-14	Darwin Molecular Corporation	Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins
MXPA03011046A (es)	2001-06-01	2004-06-25	Elan Pharm Inc	Hidroxialquilaminas.
US6906104B2 (en)	2001-06-13	2005-06-14	Pharmacia & Upjohn Company	Aminediols for the treatment of Alzheimer's disease
BR0210721A (pt) *	2001-06-27	2004-07-20	Elan Pharm Inc	Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
MXPA04000338A (es) *	2001-07-10	2004-07-23	Upjohn Co	Diamindioles para tratamiento de enfermedad de alzheimer.
BR0211121A (pt) *	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
US6943001B2 (en) *	2001-08-03	2005-09-13	Diversa Corporation	Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US6979733B2 (en) *	2001-08-03	2005-12-27	Diversa Corporation	Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
EA200400135A1 (ru) *	2001-08-31	2004-08-26	Ньюрочем ( Интернэшнл) Лимитед	Применение производных амидинов для лечения амилоидоза
EP1432674A2 (de) *	2001-10-04	2004-06-30	Elan Pharmaceuticals, Inc.	Hydroxypropylamine
AU2002359376B2 (en) *	2001-11-08	2008-01-10	Elan Pharmaceuticals, Inc.	N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214297A (pt) *	2001-11-19	2004-11-09	Upjohn Co	Métodos de tratar ou prevenir mal de alzheimer em um indivìduo e uma doença distinguida por depósitos de beta-amilóide sobre ou no cérebro, de tratar mal de alzheimer um indivìduo que apresenta, ou de prevenir que um indivìduo adquira, uma doença ou condição, de inibir atividade de beta-secretase, clivagem de um isótipo de protéina precursora amilóide e produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase e uso de um composto, e, composição
WO2003048298A2 (en) *	2001-12-05	2003-06-12	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7067321B2 (en) *	2002-02-22	2006-06-27	University Of Tennessee Research Foundation	Polyglutamine repeat sequences
WO2003076455A2 (en) *	2002-03-05	2003-09-18	Ramot At Tel-Aviv University Ltd.	Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7226771B2 (en)	2002-04-19	2007-06-05	Diversa Corporation	Phospholipases, nucleic acids encoding them and methods for making and using them
PT1497418E (pt)	2002-04-19	2013-01-25	Dsm Ip Assets Bv	Fosfolípases, ácidos nucleicos que as codificam e métodos para as preparar e utilizar
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
US20040005571A1 (en) *	2002-07-03	2004-01-08	Hawley R. Scott	Axs gene and protein and methods related thereto
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
US20040146949A1 (en) *	2002-10-25	2004-07-29	Jun Tan	Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20060206950A1 (en) *	2002-11-04	2006-09-14	Kaelin William G Jr	In vivo imaging of e2f-fegulated bioluminescent proteins
AU2003298675A1 (en) *	2002-11-22	2004-06-18	You-Jun Fei	NaCT AS A TARGET FOR LIFESPAN EXPANSION AND WEIGHT REDUCTION
CA2507484A1 (en) *	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
NZ567324A (en) *	2003-02-01	2009-08-28	Wyeth Corp	Active immunization to generate antibodies to soluble A-beta
CN102618564B (zh)	2003-03-06	2014-10-29	维莱尼姆公司	淀粉酶、编码它们的核酸及其制备和应用方法
CA3007908A1 (en)	2003-03-07	2005-04-14	Dsm Ip Assets B.V.	Hydrolases, nucleic acids encoding them and methods for making and using them
HUE030493T2 (en)	2003-04-04	2017-05-29	Basf Enzymes Llc	Pectate lyases, nucleic acids and processes encoding them for their production and use
TW200512195A (en)	2003-04-21	2005-04-01	Elan Pharm Inc	Benzamide 2-hydroxy-3-diaminoalkanes
WO2004094413A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
WO2004110350A2 (en) *	2003-05-14	2004-12-23	Torreypines Therapeutics, Inc.	Compouds and uses thereof in modulating amyloid beta
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
ATE420160T1 (de)	2003-06-18	2009-01-15	Genelux Corp	Modifizierte rekombinante vacciniaviren, verwendungen davon
US7960148B2 (en)	2003-07-02	2011-06-14	Verenium Corporation	Glucanases, nucleic acids encoding them and methods for making and using them
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
CA2535526C (en)	2003-08-11	2015-09-29	Diversa Corporation	Laccases, nucleic acids encoding them and methods for making and using them
WO2005059100A2 (en) *	2003-12-12	2005-06-30	New York University	Methods and compositions relating to cystatin c
WO2005070407A1 (en) *	2004-01-21	2005-08-04	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US7262223B2 (en) *	2004-01-23	2007-08-28	Neurochem (International) Limited	Amidine derivatives for treating amyloidosis
WO2005087714A2 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
US20060014737A1 (en) *	2004-03-09	2006-01-19	Varghese John	Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528400A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528404A (ja)	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20060019241A1 (en) *	2004-04-20	2006-01-26	Vadivel Ganapathy	Na+ and CI-coupled transport system for endogenous opioid peptides
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
WO2005110422A2 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
AU2005264938B2 (en)	2004-06-16	2011-11-24	Verenium Corporation	Compositions and methods for enzymatic decolorization of chlorophyll
US20060128715A1 (en) *	2004-07-09	2006-06-15	Jennifer Sealy	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006010095A2 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
EP1838348B1 (de)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
CA2589017A1 (en) *	2004-12-15	2006-06-22	Neuralab Limited	Amyloid beta antibodies for use in improving cognition
US7625560B2 (en) *	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
WO2006089095A2 (en)	2005-02-17	2006-08-24	Biogen Idec Ma Inc.	Treating neurological disorders
EP2886658A1 (de)	2005-03-10	2015-06-24	BASF Enzymes LLC	Lyaseenzyme, Nukleinsäuren zur Codierung davon und Verfahren zur Herstellung und Verwendung davon
CA2611859C (en)	2005-03-15	2015-03-31	Verenium Corporation	Cellulases, nucleic acids encoding them and methods for making and using them
EP1907566A4 (de) *	2005-05-27	2008-12-10	Memory Pharm Corp	Vektoren für transgenes morbus-alzheimer-mausmodell und verwendungen davon
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
EP1913017A1 (de) *	2005-08-03	2008-04-23	Boehringer Ingelheim International GmbH	Substituierte ethan-1,2-diamine zur behandlung von alzheimer-krankheit ii
US20100144681A1 (en) *	2005-08-11	2010-06-10	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
US20090042867A1 (en) *	2005-08-11	2009-02-12	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
US20100168070A1 (en) *	2005-08-11	2010-07-01	Niklas Heine	Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) *	2005-08-11	2008-04-30	Boehringer Ingelheim International GmbH	Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
EP1937638A1 (de) *	2005-10-12	2008-07-02	Elan Pharmaceuticals Inc.	Verfahren zur behandlung von amyloidose unter verwendung von aspartylproteaseinhibitor- arylcyclopropylderivaten
WO2007047305A1 (en)	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007088418A1 (en)	2006-01-31	2007-08-09	Multi Gene Vascular Systems, Inc.	Drug-eluting intravascular prostheses and methods of use
EP1987142A4 (de)	2006-02-02	2009-07-15	Verenium Corp	Esterasen und damit zusammenhängende nukleinsäuren und verfahren
US7868022B2 (en) *	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) *	2006-02-06	2010-08-17	Baxter Ellen W	2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
NZ595497A (en)	2006-02-10	2013-09-27	Verenium Corp	Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
TR201809912T4 (tr)	2006-02-14	2018-07-23	Bp Corp North America Inc	Ksilanazlar, bunları kodlayan nükleik asitler ve bunları yapmak ve kullanmak için yöntemler.
WO2007103683A2 (en) *	2006-03-01	2007-09-13	Roskamp Research Llc	Compounds for inhibiting beta-amyloid production
AU2007223086B2 (en)	2006-03-07	2013-09-26	Basf Enzymes Llc	Aldolases, nucleic acids encoding them and methods for making and using them
MX2008011477A (es)	2006-03-07	2008-09-23	Cargill Inc	Aldolasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
DK2069389T3 (en)	2006-08-04	2015-01-12	Bp Corp North America Inc	Glucanases, nucleic acids encoding them, and processes for their preparation and use
CN102886052B (zh)	2006-09-14	2014-07-30	迈德詹尼克斯医疗以色列有限公司	长效药物制剂
US8454948B2 (en)	2006-09-14	2013-06-04	Medgenics Medical Israel Ltd.	Long lasting drug formulations
ES2531135T3 (es)	2006-09-21	2015-03-11	Basf Enzymes Llc	Fitasas, ácidos nucleicos que las codifican y métodos para su producción y uso
EP2057274B1 (de)	2006-09-21	2013-12-11	DSM IP Assets B.V.	Phospholipase ,nukleinsaüre, die diese kodieren und verfahren zur ihrer herstellung und verwendung
DK2089417T3 (en)	2006-10-12	2015-03-23	Bhi Ltd Partnership	Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8188046B2 (en) *	2006-10-16	2012-05-29	University Of South Florida	Amyloid beta peptides and methods of use
EP2120557A4 (de) *	2006-12-08	2010-02-10	Roskamp Res Llc	Polyhydrochinolinverbindungen und dihydropyridinverbindungen zur hemmung der beta-amyloid-produktion
PL2479267T3 (pl)	2006-12-21	2017-06-30	Basf Enzymes Llc	Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich
US7618944B2 (en) *	2007-03-01	2009-11-17	Intezyne Technologies, Inc.	Encapsulated amyloid-beta peptides
EP2134863B1 (de)	2007-03-13	2014-05-21	The Children's Hospital Of Philadelphia	Genetische veränderungen auf chromosom 16 und verfahren zur verwendung davon bei der diagnose von typ-1-diabetes
WO2008152507A2 (en)	2007-03-16	2008-12-18	Multigene Vascular Systems, Inc.	Compositions and methods for treating ophthalmic disorders
EP2144935A2 (de)	2007-03-29	2010-01-20	Technion Research & Development Foundation Ltd.	Antikörper, methoden und kits zur diagnose und behandlung von melanomen
US20080292625A1 (en) *	2007-04-18	2008-11-27	Sally Schroeter	Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) *	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8222264B2 (en)	2007-07-06	2012-07-17	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
DK2182983T3 (da)	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
AU2008297070A1 (en) *	2007-09-12	2009-03-19	Probiodrug Ag	Transgenic mice
BRPI0817811A2 (pt)	2007-10-03	2014-10-14	Verenium Corp	Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2217721A4 (de) *	2007-10-29	2013-01-09	Univ California	Osteoarthritis-gentherapie
WO2009088753A1 (en)	2008-01-03	2009-07-16	Verenium Corporation	Isomerases, nucleic acids encoding them and methods for making and using them
CN104651381A (zh)	2008-01-03	2015-05-27	巴斯夫酶有限责任公司	转移酶和氧化还原酶、编码它们的核酸以及其制备和应用方法
WO2009097278A1 (en) *	2008-01-28	2009-08-06	Janssen Pharmaceutica N.V.	6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US8420088B2 (en)	2008-01-28	2013-04-16	Novartis Ag	Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en)	2008-01-28	2009-09-01	Novartis Ag	Methods and compositions using Klotho-FGF fusion polypeptides
EP2240472B1 (de) *	2008-01-29	2012-11-21	Janssen Pharmaceutica NV	Als inhibitoren von beta-sekretase (bace) geeignete 2-aminochinolinderivate
AU2009215441B2 (en)	2008-02-19	2015-07-02	The Children's Hospital Of Philadelphia	Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
CA2724475C (en)	2008-05-16	2019-05-07	The Children's Hospital Of Philadelphia	Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
US8198062B2 (en)	2008-08-29	2012-06-12	Dsm Ip Assets B.V.	Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en)	2008-08-29	2012-04-10	Bunge Oils, Inc.	Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en)	2008-08-29	2013-01-22	Bunge Oils, Inc.	Hydrolases, nucleic acids encoding them and methods for making and using them
AU2009290563A1 (en)	2008-09-15	2010-03-18	Genentech, Inc.	Compositions and methods for regulating cell osmolarity
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
NZ596459A (en)	2009-05-21	2013-11-29	Verenium Corp	Phytases, nucleic acids encoding them and methods for making and using them
US8324450B2 (en)	2009-06-02	2012-12-04	Academia Sinica	Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
UA109884C2 (uk)	2009-10-16	2015-10-26		Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
UA111708C2 (uk)	2009-10-16	2016-06-10	Бандж Ойлз, Інк.	Спосіб рафінування олії
CA2802726A1 (en)	2010-06-15	2011-12-22	Medgenics Medical Israel Ltd.	Long lasting drug formulations
ES2705027T3 (es)	2010-08-19	2019-03-21	Buck Institute For Age Res	Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
WO2013027191A1 (en)	2011-08-25	2013-02-28	Novartis Ag	Methods and compositions using fgf23 fusion polypeptides
ES2724803T3 (es)	2011-12-16	2019-09-16	Univ Leland Stanford Junior	Polipéptidos opsinas y métodos de utilización de los mismos
CN104270945B (zh)	2012-03-19	2017-03-29	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
CA2899938C (en)	2013-02-12	2021-10-19	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
JP6621747B2 (ja)	2013-08-14	2019-12-18	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	疼痛を制御するための組成物及び方法
EP3060144A1 (de)	2013-10-24	2016-08-31	Medgenics Medical Israel, Ltd	Mikroorganen zur verzögerten freisetzung eines therapeutischen polypeptids und verfahren zur verwendung davon
CN106459138A (zh)	2014-03-28	2017-02-22	斯坦福大学托管董事会	工程化的光激活阴离子通道蛋白及其使用方法
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
HK1244511A1 (zh)	2014-10-29	2018-08-10	The Children's Hospital Of Philadelphia	与嗜酸细胞食管炎相关的基因改变的诊断和治疗
AU2015356643B2 (en)	2014-12-04	2019-01-24	Novartis Ag	Methods and compositions using Klotho variant polypeptides
EP3730188B1 (de)	2015-08-21	2024-07-31	The Children's Hospital of Philadelphia	Zusammensetzungen und verfahren zur verwendung in kombination zur behandlung und diagnose von autoimmunerkrankungen
EP3341362B1 (de)	2015-08-27	2023-07-05	Nantneuro, LLC	Zusammensetzungen zur app-selektiven bace-hemmung und verwendungen dafür
US10667691B2 (en)	2015-08-31	2020-06-02	The Board Of Trustees Of The Leland Stanford Junior University	Compressed sensing high resolution functional magnetic resonance imaging
KR102893860B1 (ko)	2015-12-09	2025-12-03	더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티	기능적 뇌 회로 분석법
WO2017136285A1 (en)	2016-02-01	2017-08-10	The Board Of Trustees Of The Leland Stanford Junior University	Method and systems for analyzing functional imaging data
EP3455223B1 (de)	2016-05-12	2023-11-08	Buck Institute for Research on Aging	Verbindungen zur förderung der normalen verarbeitung von app
IL265486A (en)	2019-03-19	2020-09-30	Yeda Res & Dev	Type II stable opsins and methods of using them
CN116832146B (zh) *	2023-06-30	2024-02-13	广东暨安特博生物科技有限公司	Il-27蛋白在制备治疗阿尔茨海默症的产品的应用
WO2025189030A1 (en)	2024-03-07	2025-09-12	Stellaromics, Inc.	Methods and systems for volumetric imaging

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989006693A1 (en) *	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic sequences coding for alzheimer amyloid from brain
AU3056289A (en) *	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
EP0451700A1 (de) *	1990-04-10	1991-10-16	Miles Inc.	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
WO1992006187A1 (en) *	1990-09-28	1992-04-16	The Upjohn Company	Transgenic animals with alzheimer's amyloid precursor gene
US5672805A (en) *	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein

1991
- 1991-06-17 ES ES91912653T patent/ES2217250T3/es not_active Expired - Lifetime
- 1991-06-17 EP EP91912653A patent/EP0647268B1/de not_active Expired - Lifetime
- 1991-06-17 AU AU82102/91A patent/AU646877B2/en not_active Expired
- 1991-06-17 WO PCT/US1991/004447 patent/WO1991019810A1/en not_active Ceased
- 1991-06-17 JP JP3511791A patent/JPH06507782A/ja active Pending
- 1991-06-17 CA CA002085127A patent/CA2085127C/en not_active Expired - Lifetime
- 1991-06-17 US US07/716,725 patent/US5387742A/en not_active Expired - Lifetime
- 1991-06-17 AT AT91912653T patent/ATE260974T1/de not_active IP Right Cessation
- 1991-06-17 DE DE69133372T patent/DE69133372T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0647268A4 (de)	1993-05-27
CA2085127A1 (en)	1991-12-16
AU646877B2 (en)	1994-03-10
EP0647268B1 (de)	2004-03-03
JPH06507782A (ja)	1994-09-08
ATE260974T1 (de)	2004-03-15
US5387742A (en)	1995-02-07
ES2217250T3 (es)	2004-11-01
AU8210291A (en)	1992-01-07
EP0647268A1 (de)	1995-04-12
DE69133372T2 (de)	2005-02-24
WO1991019810A1 (en)	1991-12-26
DE69133372D1 (de)	2004-04-08

Legal Events

Date	Code	Title	Description
1994-08-15	EEER	Examination request
2011-06-17	MKEX	Expiry

Publication	Publication Date	Title
CA2085127C (en)	2002-12-10	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5912410A (en)	1999-06-15	Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US6211428B1 (en)	2001-04-03	Transgenic mouse expressing a familial form of human amyloid precursor protein
AU671093B2 (en)	1996-08-15	Transgenic animal models for alzheimer's disease
US6037521A (en)	2000-03-14	Transgenic mouse expressing an β-Amyloid transgene
US5672805A (en)	1997-09-30	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US6262335B1 (en)	2001-07-17	Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
US6018097A (en)	2000-01-25	Transgenic mice expressing human insulin
WO1994023049A2 (en)	1994-10-13	The introduction and expression of large genomic sequences in transgenic animals
EP0451700A1 (de)	1991-10-16	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
WO1994023049A9 (en)	1994-11-24	The introduction and expression of large genomic sequences in transgenic animals
EP0550675A1 (de)	1993-07-14	Alzheimeramyloidvorläufersgen enthaltende transgentiere
Loring et al.	1996	Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent
WO1994012627A1 (en)	1994-06-09	Transgenic animal model for alzheimer's disease
US6734336B1 (en)	2004-05-11	Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring
JP5046413B2 (ja)	2012-10-10	ヒトｆａｄプレセニリン突然変異をもつ標的遺伝子組換え非ヒト哺乳動物および生殖による子孫
JP2002142610A (ja)	2002-05-21	Ａｌｓモデルラット
AU2001276995A1 (en)	2002-05-02	Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring
Beech	1994	On the causes of Alzheimer's disease: Investigations using transgenic mouse model systems